Advanced search
Publication Cover
Scandinavian Journal of Gastroenterology Volume 37, 2002 - Issue 2
Submit an article Journal homepage
37
Views
16
CrossRef citations to date
0
Altmetric
Research Article

Aminosalicylates: Potential Antineoplastic Actions in Colon Cancer Prevention

Hubert Allgayer
&
Wolfgang Kruis
Pages 125-131 | Published online: 08 Jul 2009

  • Boring CC, Squires TS, Tong T. Cancer Statistics 1994. Cancer J Clin 1994;44:7-26.
  • DuBois RN, Giaidello BM, Smalley WE. Nonsteroidal antiinflammatory drugs, eicosanoids, and colorectal cancer prevention. Gastroenterol Clin North Am 1996;25:773-91.
  • Thun MJ, Namboodiri MM, Heath CW Jr. Aspirin use and reduced risk of fatal colon cancer. N Engl J Med 1991;325: 1593-6.
  • Giovannucci E, Egan KM, Hunter DJ, Stampfer MJ, Colditz GA, Willet WC, et al. Aspirin and the risk of colorectal cancer in women. N Engl J Med 1995;333:609-14.
  • Peleg II, Maibach HT, Brown SH, Mel Wilcox M. Aspirin and nonsteroidal anti-inflammatory drug use and the risk of subsequent colorectal cancer. Arch Intern Med 1994;154:394-9.
  • Pinczowski D, Ekbom A, Baron J, Yuen J, Adami HO. Risk factors for colorectal cancer in patients with ulcerative colitis: a case control study. Gastroenterology 1994;107:117-20.
  • Ekbom A, Kornfeld D. Sulphasalazine use as a preventive factor for colorectal cancer in ulcerative colitis patients-a review. Inflamm Bowel Dis 1996;2:276-8.
  • Moody GA, Jayanthi V, Probert CSJ, MacKay H, Mayberry JF. Long-term therapy with sulphasalazine protects against colorectal cancer in ulcerative colitis: a retrospective study of colorectal cancer risk and compliance with treatment in Leicestershire. Eur J Gastroenterol Hepatol 1996;8:1179-83.
  • Eaden J, Abrams K, Ekbom A, Jackson E, Mayberry J. Colorectal cancer prevention in ulcerative colitis: a case control study. Aliment Pharmacol Therap 2000;14:145-53.
  • Eberhart CE, Coffey RJ, Radhika A, Giardiello FM, Ferrenbach S, DuBois RN. Up-regulatio n of cyclooxygenas e 2 gene expression in human colorectal adenomas and adenocarcinomas. Gastroenterology 1994; 107:1183-8.
  • Bus PJ, Verspaegt HW, Lamers CBMW, Griffinen G. Chemoprevention of colorectal cancer by non-steroidal anti-inflammatory drugs. Scand J Gastroenterol 2000;35 Suppl 232:101 -4
  • Vainio H, Morgan G. Non-steroidal anti-inflammatory drugs and the chemoprevention of gastrointestinal cancers. Scand J Gastroenterol 1998;33:785-9.
  • Jänne PA, Mayer RJ. Chemoprevention of colorectal cancer. N Engl J Med 2000;342:1960-8.
  • Herfarth H, Schölmerich J. Colorectal cancer chemopre ventio n in ulcerative colitis. Z Gastroenterol 2000;38:923-5
  • Pollard M, Luckert PH. Indomethacin treatment of rats with dimethylhydrazine-induce d tumors. Cancer Treat Rep 1980;64: 1323-7.
  • Reddy BS, Maruyama H, Kelloff G. Dose-related inhibition of colon carcinogenesi s by dietary piroxicam, a non-steroidal antiinflammatory drug during different stages of rat colon tumor development. Cancer Res 1987;47:5340-6.
  • Norisarou T, Satoh M, Nano M, Takahashi T. Inhibition of initiation and promotion by N-methyl-nitroso urea induced carcinogenesi s in rats by non-steroid antiinflammatory drug indomethacin. Carcinogenesi s 1982;4:1225-7.
  • Barnes CJ, Hardman WE. Cameron IL, Lee M. Aspirin, but not sodium salicylate, indomethacin or nabumetone, reversibly suppresses 1,2 dimethylhydrazine-induce d colonie aberrant crypt foci in rats. Dig Dis Sci 1997;42:920-6.
  • Davis AE, Patterson F, Crouch R. The effect of therapeutic drugs used in inflammatory bowel disease on the incidence and growth of colonie cancer in the dimethylhydrazin e rat model. Br J Cancer 1992;66:777-80.
  • DuBois RN, Radhika A, Reddy BS, Entingh AJ. Increased cyclooxygenase-2 levels in carcinogen-induced rat colonie tumors. Gastroenterology 1996; 110:1259-62.
  • Grisham MB, Ware K, Marshall S, Yamada T, Sandhu IS. Prooxidant properties of 5-aminosalicylic acid. Possible mechanisms for its adverse side effects. Dig Dis Sci 1992;37:1383 -9.
  • Hixson LJ, Alberts DS, Krutsch M, Einsphr J, Brendel K, Gross PH, et al. Antiproliferative effect of nonsteroidal antiinflammatory drugs against human colon cancer cells. Cancer Epidemiol Biomarkers Prev 1994;3:433-8.
  • Brown WA, Farmer KC, Kinner SA, Malcontenti-Wilson C, Misajon A, O'Brian PE. 5-aminosalicylic acid and olsalazine inhibit tumor growth in a rodent model of colorectal cancer. Dig Dis Sci 2000:45:1578-84.
  • Moser AR, Pilot HC, Dove WF. A dominant mutation that predisposes to multiple intestinal neoplasia in the mouse. Science 1990:247:322-4.
  • Oshima H, Oshima M, Kobayashi M, Tsutsumi M, Taketo MM. Morphological and molecular processes of polyp formation in the Ape ?716 knockout mice. Cancer Res 1997;57:1644-9.
  • Beazer-Barclay Y, Levi DB, Moser AR, Dove WF, Hamilton SR, Vogelstein B, et al. Sulindac suppresses tumurigenesis in themin mouse. Carcinogenesis 1996;17:1757-60.
  • Barnes CJ, Lee M. Chemoprevention of spontaneaus intestinal adenomas in the adenomatous polyposis coli min mouse model with aspirin. Gastroenterology 1998; 114:873-7.
  • Jacoby RF, Marshall DJ, Newton MA, Novakovic K, Tutsch K, Cole CE, et al. Chemoprevention of spontaneous intestinal adenomas in the APC mouse model by the non steroidal antiinflammatory drug piroxicam. Cancer Res 1996;56:710-4.
  • Prakash A, Spencer CM. Balsalazide. Drugs 1998;56:83-9.
  • MacGregor DJ, Korn YS, Sidditi BB, Kwan I, Sleisenger M, Johnson LK. Induction of colon cancer cell apoptosis in vitro and inhibition of intestinal tumor formation in Min/+ mice by balsalazide and metabolites. Gastroenterology 1996;110:A553.
  • Ritland SR, Leigthon JA, Hirsch RE, Morrow JD, Weaver AL, Gendler SJ. Evaluation of 5-aminosalicylic acid (5-ASA) for cancer chemoprevention : lack of efficacy against nascent adenomatous polyps in the Ape (Min) mouse. Clin Cancer Res 1999:5:855-63.
  • Shinozaki M, Nagawa K, Watanabe T, Saki T, Muto T. Acetateinduced colitis promotes dimethylhydrazine-induce d colonie tumors. Gastroenterology 1999;116:A502.
  • Okayasu I, Ohkusa T, Kajiura K, Kanno J, Sakamoto S. Promotion of colorectal neoplasia in experimental murine ulcerative colitis. Gut 1996;39:87-92.
  • Isomaki HA, Hakulinen T, Joutsenlahti U. Excess risk of lymphomas, leukemia and myeloma in patients with rheumatoid arthritis. J Chron Dis 1978;31:691-6.
  • Rosenberg L, Palmer JR, Zauber AG, Warshauer ME, Stolley PD, Shapiro S. A hypothesis: non-steroidal anti-inflammatory drugs reduce the incidence of large bowel cancer. J Nath Cancer Inst 1991;83:355-8.
  • Schreinemachers DM, Eversen RB. Aspirin use and lung, colon and breast cancer incidence in a prospective study. Epidemiology 1994:5:138-46.
  • Thun MJ, Calle EE, Namboodiri MM, Flanders WD, Coates RJ, Byers T, et al. Risk factors for fatal colon cancer in a large prospective study. J Natl Cancer Inst 1992;84:1491 -500.
  • Gann PH, Manson JE, Glynn J, et al. Low dose aspirin and incidence of colorectal tumors in a randomiced trial. J Natl Cancer Inst 1993:85:1220-4.
  • Smalley W, Rav WA, Daugherty J. Use of non-steroidal antiinflammatory drugs and incidence of colorectal cancer: a population-based study. Arch Int Med 1999;159:161-4.
  • Greenberg ER, Baron JA. Aspirin and other nonsteroid antiinflammatory drugs as cancer-preventiv e agents. IARC Sci Publ 1996;139:91-6.
  • Stein RB, Hanauer SB. Medical therapy for inflammatory bowel disease. Gastroenterology Clin North Am 1999;28:297-321.
  • Allgayer H. Sulfasalazine and 5-ASA compounds. Gastroenterol Clin North Am 1992;21:643-58.
  • Bus PJ, Nagtegaal ID, Verspaget HW, Lamers CB, Geldorf H, Van Krieken JH, et al. Mesalazine-induced apoptosis of colorectal cancer: on the verge of a new chemopreventive era? Aliment Pharmacol Ther 1999:13:1397-402.
  • Reinacher-Schick A, Scidensticker F, Petrasch S, Reiser M, Philippopu S, Theegarten D, et al. Mesalazine changes apoptosis and proliferation in normal mucosa of patients with sporadic polyps of the large bowel. Endoscopy 2000;32:24554.
  • Thompson CB. Apoptosis in the pathogenesis and treatment of disease. Science 1995;267:1456-62.
  • Hall PA, Coates PJ, Adsari B, Hopwood D. Regulation of cell number in the mammalian gastrointestinal tract: the importance of apoptosis. J Cell Sci 1994;107:3569-77.
  • Chan TA, Morin PJ, Vogelstein B, Kinder KW. Mechanisms underlying nonsteroidal antiinflammalory drug-mediated apoptosis. Proc Natl Acad Sci USA 1998;681-6.
  • Bedi A, Pasricha PJ, Akhtar AI, Barber JP, Bedi GC, Giaidiello FM, et al. Inhibition of apoptosis during development of colorectal cancer. Cancer Res 1995;55:1811 -6.
  • Hanif R, Pittas A, Feng Y, Koutsos MI, Quiao L, Staiano-Coico L, et al. Effect of nonsteroidal anti-inflammatory drugs on proliferation and on induction of apoptosis in colon cancer cell s by a prostaglandin-independen t pathway. Biochem Pharmacol 1996;52:237-45.
  • Williams CW, DuBois RN. Prostaglandin endoperoxide synthetase: Why two isoforms? Am J Physiol 1996;270:G393 -400.
  • Kargmann SL, O'Neil GP, Vickers PJ, Evans JF, Mancini JB, Jothy S. Expression of prostaglandin G/H synthetase-1 and -2 protein in human colon cancer. Cancer Res 1995;55:3556-9.
  • Eberhart CE, Coffey RJ, Radhika A, Giaidello FM, Ferrenbach S, DuBois RN. Up-regulation of cyclocoxygenas e 2 gene expression in human colorectal adenomas and adenocarcinomas. Gastroenterology 1994; 107:1183-8.
  • Fujita T, Matsui M, Takaku K, Uetake H, Ichikawa W, Taketo MM, et al. Size- and invasion-dependen t increase in cyclooxygenase 2 levels in human colorectal carcinoma. Cancer Res 1998;58:4823-6.
  • Williams CS, Luongo C, Radhika A, Zhang T, Lamps L, Nanney LB, et al. Elevated cyclooxygenase-2 levels in Min mouse adenomas. Gastroenterology 1996;111:1134-40.
  • Tsujii M, Kawano S, DuBois RN. Alterations in cellular adhesion and apoptosis in epithelial cells overexpressing prostaglandin endoperoxide synthetase-2. Cell 1995;83:493-501.
  • Oshima M, Dichuk JE, Kargman SL, Oshima H, Hancock B, Kwong E, et al. Suppression of intestinal polyposis in Ape47 knockout mice by inhibition of cyclooxygenase-2 (COX-2). Cell 1996;87:803-9.
  • Saunders MA, Belvisi MG, Barnes PJ, Williams TJ, Mitchell JA. Comparison of the effects of nonsteroidal anti-inflammatory drugs as inhibitors of COX-2 metabolites derived from endogenous vs. exogenous arachidonic acid. Br J Pharmacol 1996; 117:80P.
  • Hawkey CJ, Rampton DS. Prostaglandin s and the gastrointestinal mucosa: are they important in its function, disease or treatment? Gastroenterology 1985;89:1162-8.
  • Sharon P, Ligumsky M, Rachmilewitz D, Zor U. Role of prostaglandin s in ulcerative colitis. Enhanced production during active disease and inhibition by sulfasalazine. Gastroenterology 1978;75:638-40.
  • Dittmann KH, Mayer CK, Rodemann HP, Pendes PE, Denzlinger C. MK 886, a leukotriene biosynthesis inhibitor, induces antiproliferative effects and apoptosis in HL-60 cells. Leukemia Res 1998;52:491 -93.
  • Porreca E, Di Febbo C, Di Sciullo A, Angelucci C, Nasuti M, Vitullo P, et al. Cysteinyl leukotriene D4 induced vascular smooth muscle cell proliferation : a possible role in myointimal hyperplasia. Thromb Haemost 1996;76:99-104.
  • Allgayer H, Stenson WF. A comparison of effects of sulfasalazine and its metabolites on the metabolism of endogenous vs. exogenous arachidonic acid. Immunopharmacology 1988; 15:39-44.
  • Elliot GR, Tak C, Bonta K. Prostaglandin E2 enhances, and leukotriene C4 inhibits interleukin-1 inhibition of WEHJ-38 cell growth. Cancer Immunol 1989;28:74-6.
  • Riuox N, Castonguay A. Inhibitors of lipoxygenase : a new class of chemopreventive agents. Carcinogenesi s 1998; 19:1393-400.
  • Rampton DS, Hawkey CJ. Prostaglandin s and ulcerative colitis. Gut 1984;25:1399-413.
  • Piazza GA, Albert DS, Hixon LJ, Paranka NS, Li HFT, Bogert C, et al. Sulindac sulfone inhibits azooxymethane-induce d colon carcinogenesis in rats without reducing prostaglandin levels. Cancer Res 1997;75:2909-15.
  • Elder DJE, Hague A, Hicks DJ, Paraskeva C. Differential growth inhibition by the aspirin metabolite salicylate in human colorectal tumor cell lines: enhanced apoptosis in carcinoma and in vitro-transformed adenoma relative to adenoma cell lines. Cancer Res 1996;56:2273-6.
  • Shiff SJ, Qiao L, Tsai LL, Rigas. Sidindac-sulfide, an aspirinlike compound, inhibits proliferation, causes cell cycle quiescence, and induces apoptosis in HT-29 colon adenocarcinoma cells. J Clin Invest 1995;96:491-503.
  • Goldberg Y, Nassif D, Pittas A, Tsai LL, Dynalcht BD, Rigas B, et al. The antiproliferativ e effect of sulindac and sulindac sulfide on HT-29 colon cancer cells: alterations in tumor suppressor and cell cycle regulatory proteins. Oncogene 1996; 12:893-901.
  • Hinz M, Krappmann D, Eichten A, Heder A, Scheidereit C, Strauss M. NF-kB function in growth control: regulation of cyclin Dl expression and Go/Gl-to-S-phase transition. MoI Cell Biol 1999; 19:2690-8.
  • Schmid RM, Adler G. NF-kB/Rel/IkB: implications in gastrointestinal diseases. Gastroenterology 2000; 118:1208-28.
  • Gilmore TD. Malignant transformation by mutant ReI proteins. Trends Genet 1991;7:318-22.
  • Luque J, Gelinas C. Rel/NF-Kappa B and/Kappa B factors in oncogenesis. Semin Cancer Biol 1997;8:103-11.
  • Neumann M, Marienfeld R, Sending E. Rel/NF-Kappa B transcription factors and cancer: oncogenesis by deregulated transcription [Review]. Int JOncol 1997;! 1:1335-47.
  • Wang CY, Mayo MW, Komduk RG, Goeddel DV, Baldwin AS. NF-kB antiapoptosis: induction of TRAF-I, and TRAF-2 and c-IAPl and C-IAP2 to suppress caspase-8 activation. Science 1998;281:1680-3.
  • Kopp E, Ghosh S. Inhibition of NF-kB by sodium salicylate and aspirin. Science 1994;265:956-9.
  • Yin MJ, Yamamoto Y, Gaynor RB. The anti-inflammatory agents aspirin and salicylate inhibit the activity of DcB kinase B. Nature 1998;396:77-80.
  • Egan LJ, Mays DC, Huntoon CJ, Bell MP, Pike MG, Sandborn WJ, et al. Inhibition of interleukm-l-stimulated NF-kappa B RelA/p65 phosphorylatio n by mesalamine is accompanied by decreased transcriptional activity. J Biol Chem 1999;274: 26448-53.
  • Kaiser GC, Yan F, Polk DB. Mesalamine blocks tumor necrosis factor growth inhibition and nuclear factor kB activition in mouse colonocyte. Gastroenterology 1999; 116:602-9.
  • Weber CK, Liptay S, Wirth T, Adler G. Suppression of NfkB activity by sulfasalazine is mediated by direct inhibition of I*B kinases á and B. Gastroenterology 2000; 119:1209-288.
  • Sinicrope FA, Ruan SB, Cleary KR, Clifton Stephens LJ, Lee JJ, Levin B. Bcl-2 and p53 oncoprotein expression during colorectal carcinogenesis. Cancer Res 1995;55:237-41.
  • Baretton GB, Diebold J, Christoforis G, Vogt M, Müller C, Dopfer K, et al. Apoptosis and immunohistochemical bcl-2 expression in colorectal adenomas and carcinomas. Cancer 1996;77:255-64.
  • Sheng H, Shao J, Morrow JD, Beauchamp RD, DuBois RN. Modulation of apoptosis and bcl-2 expression by prostaglandi n E2 in human colon cancer cells. Cancer Res 1998;58:362-6.
  • Tillmann T, Hombach A, Diehl V, Kruis W, Abken H, Pohl C. Inhibition of expression of bcl-2 as a possible mechanism of action of the chemopreventive effect of salicylic acid in colon carcinoma. Z Gastroenterol 1998;36:A706.
  • He TC, Chan TA, Vogelstein B, Kinkier KW. PPAR-d is an APC-regulated target of nonsteroidal anti-inflammatory drugs. Cell 1999;99:335-45.
  • Wu GD. A nuclear receptor to prevent colon cancer. N Engl J Med 2000;342:651-3.
  • Loft S, Poulsen HE. Cancer risk and oxidative DNA damage in man. J MoI Med 1996;74:297-312.
  • Malins DC, Haimanot R. Major alterations in the nucleotide structure of DNA in cancer of the female breast. Cancer Res 1991;51:5430-2.
  • Farinati F, Cardin R, Rugge M, Mario F, Bonvicini P, Naccarato R. Oxidative DNA damage accumulation in gastric carcinogenesis. Gut 1998;42:351-6.
  • Halliwell B. Establishing the significance and optimal intake of dietary antioxidants : the biomarker concept. Nutr Rev 1999;57: 104-13.
  • Bartsch H, Nair J, Owen RW. Dietary polyunsaturated fatty acids and cancers of the colorectum: emerging evidence for their role as risk modifiers. Carcinogenesi s 1999;20:2209-18.
  • Noroozi M, Angerson WB, Lean M. Effects of flavonoids and vitamine C on oxidative DNA damage to human lymphocytes. Am J Clin Nutr 1998;67:1210-8.
  • Chang CL, Ha HT, Ricciardello L, Chang DK, Randolph A, Chauhan DP et al. The DNA mismatch repair (MMR) system is inappropriately down-regulated in the presence of oxidative DNA damage. Gastroenterology 1999;116:A386.
  • Halliwell B. Free radicals, antioxidants, and human disease: curiosity, cause or consequence? Lancet 1994;344:721-4.
  • Owen RW, Spiegelhalder B, Bartsch H. Generation of reactive oxygen species by the faecal matrix. Gut 2000;46:225-32.
  • McKenzie SM, Doe WF, Buffinton GD. 5-aminosalicylic acid prevents oxidant mediated damage of glyceraldehyde-3-phos phate dehydrogenase in colon epithelial cells. Gut 1999;44: 180-5.
  • Allgayer H, Höfer P, Schmidt M, Bohne P, Kruis W, Gugler R. Superoxide, hydroxyl and fatty acid radical scavenging by aminosalicylates. Direct evaluation with electron spin resonance spectroscopy. Biochem Pharmacol 1992;43:259-62.
  • Allgayer H, KoIb M, Stuber V, Kruis W. Modulation of base hydroxylatio n by bile acids and salicylates in a model of human colonie mucosal DNA: putative implications in colonie cancer. Dig Dis Sci 1999;44:761 -7.
  • Nashibayashi H, Kanayama S, Shinomura Y, Miyagawas J, Arioshi T, Toyota M. Decrease of oxidative DNA damage in human colonie mucosa with ulcerative colitis after the medical therapy. Gastroenterology 1999;116:A475.
  • Allgayer H. Oxygen radicals in the mucosa. In: Stange EF, editor. Chronic inflammatory bowel disease. Dordrecht, Boston, London: Kluwer Academic Press; 1995. p. 63-70.
  • Grisham MB. Effect of 5-aminosalicylic acid in fenous-sulfate mediated damage to deoxyribose. Biochem Pharmacol 1990;39: 2060-3.
  • Allgayer H, Gugler R, Bohne P, Schmidt M, Kruis W. Different iron-chelatmg properties of aminosalicylates. Gastroenterology 1992:103:1991-2 (corr.).
  • Langman M, Boyle P. Chemoprevention of colorectal cancer. Gut 1998:43:585-8.
  • Steinbach G, Lynch PM, Phillips RKS, Wallace HM, Hawk E, Gordon GB, et al. The effect of celecobix, a cyclooxygenas e inhibitor, in familial adenomatous polyposis. N Engl J Med 2000:342:1946-52.
  • Walker AM, Szneke P, Bianchi LA, Field LG, Sutherland LR, Dreyer NA. 5-aminosalicylates, sulfasalazine, steroid use, and complications in patients with ulcerative colitis. Am J Gastroenterol 1997;92:816-20.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.